2025. Efficacy and Safety of IL-5 Pathway-Targeting Biologics (Mepolizumab, Reslizumab, Benralizumab) in the Management of Hypereosinophilic Syndromes: A Systematic Review and Meta-Analysis. Open Access Indonesian Journal of Medical Reviews. 5, 5 (Sep. 2025), 607–626. DOI:https://doi.org/10.37275/oaijmr.v5i5.780.